Connor Clark & Lunn Investment Management Ltd. Buys 13,422 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Connor Clark & Lunn Investment Management Ltd. grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 22.4% during the 3rd quarter, HoldingsChannel reports. The firm owned 73,320 shares of the biopharmaceutical company’s stock after purchasing an additional 13,422 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Alnylam Pharmaceuticals were worth $20,165,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its stake in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $26,000. Huntington National Bank lifted its holdings in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $29,000. Finally, Altitude Crest Partners Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $30,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $248.79 on Thursday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The company has a market capitalization of $32.09 billion, a price-to-earnings ratio of -94.96 and a beta of 0.39. The firm’s fifty day moving average price is $273.83 and its two-hundred day moving average price is $236.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The firm’s revenue was down 33.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.15 EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ALNY. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.